Fate Therapeutics (FATE) Stock Forecast & Price Target

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

$5.04

-0.23 (-4.36%)

(As of 04/18/2024 ET)

Fate Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 12 Analyst Ratings

Analysts' Consensus Price Target

$6.73
33.48% Upside

High Forecast	$10.00
Average Forecast	$6.73
Low Forecast	$5.00

Type	Current Forecast 4/19/23 to 4/18/24	1 Month Ago 3/20/23 to 3/19/24	3 Months Ago 1/19/23 to 1/19/24	1 Year Ago 4/19/22 to 4/19/23
Consensus Rating	Hold	Hold	Hold	Hold
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	2 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)
Hold	9 Hold rating(s)	8 Hold rating(s)	7 Hold rating(s)	15 Hold rating(s)
Sell	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$6.73	$6.80	$6.31	$17.93
Predicted Upside	33.48% Upside	32.08% Upside	70.63% Upside	57.38% Upside

Get Fate Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

FATE Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

FATE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Fate Therapeutics Stock vs. The Competition

Type	Fate Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.08	2.68	2.49
Consensus Rating	Hold	Moderate Buy	Hold
Predicted Upside	33.48% Upside	941.95% Upside	12.29% Upside
News Sentiment Rating	Positive News	Neutral News	Positive News

Recent Analyst Ratings and Stock Forecasts

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
4/11/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold
3/28/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Underperform ➝ Underperform	$2.00 ➝ $6.00	-19.25%
3/19/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$7.00	-0.57%
2/27/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$3.00 ➝ $7.00	+0.72%
2/27/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$6.00 ➝ $10.00	+38.89%
2/27/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Market Perform ➝ Market Perform	$6.00 ➝ $7.00	-2.78%
2/27/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$3.00 ➝ $7.00	+0.72%
2/27/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
11/20/2023	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$12.00 ➝ $8.00	+198.51%
11/9/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$6.00 ➝ $5.00	+104.92%
9/7/2023	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$5.00	+102.43%
8/16/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold	$7.00	+146.48%
5/4/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target		$5.30 ➝ $5.00	-20.38%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 07:33 PM ET.

FATE Price Target - Frequently Asked Questions

What is Fate Therapeutics's consensus rating and price target?: According to the issued ratings of 12 analysts in the last year, the consensus rating for Fate Therapeutics stock is Hold based on the current 1 sell rating, 9 hold ratings and 2 buy ratings for FATE. The average twelve-month price prediction for Fate Therapeutics is $6.73 with a high price target of $10.00 and a low price target of $5.00. Learn more on FATE's analyst rating history.
Do Wall Street analysts like Fate Therapeutics more than its competitors?: Analysts like Fate Therapeutics less than other Medical companies. The consensus rating for Fate Therapeutics is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how FATE compares to other companies.
Does Fate Therapeutics's stock price have much upside?: According to analysts, Fate Therapeutics's stock has a predicted upside of 25.38% based on their 12-month stock forecasts.

What analysts cover Fate Therapeutics?: Fate Therapeutics has been rated by Bank of America, Barclays, BMO Capital Markets, HC Wainwright, Morgan Stanley, Needham & Company LLC, Oppenheimer, and Wedbush in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:FATE) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Fate Therapeutics (FATE) Stock Forecast & Price Target

Fate Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

Analysts' Consensus Rating

Analysts' Consensus Price Target

FATE Analyst Ratings By Month

FATE Price Targets by Month

Fate Therapeutics Stock vs. The Competition

Recent Analyst Ratings and Stock Forecasts

FATE Price Target - Frequently Asked Questions

Stock Ratings Reports and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info